Purpose: We evaluated the eŠect of intravenous administration of gadoxetic acid disodium to hepatic lesions and liver parenchyma on T 2 -weighted (T 2 WI) and diŠusion-weighted imaging (DWI).
Introduction
Gadoxetic acid disodium (Primovist, Bayer Schering Pharma, Berlin, Germany) is a recently introduced liver-speciˆc magnetic resonance (MR) contrast agent with both dynamic and hepatocytespeciˆc properties. [1] [2] [3] [4] [5] Uptake by hepatocytes of approximately half the injected dose of gadoxetic acid improves detection of liver malignancies on hepatocyte-phase imaging. [6] [7] [8] When gadoxetic acid is used, hepatocyte-phase imaging can be acquired 10 to 20 min after injection of the contrast material. 9 Performing T 2 -weighted (T 2 WI) and diŠusion-weighted imaging (DWI) during the interval between the early dynamic and hepatocyte phasesis reasonable and can shorten examination time in the busy clinical practice. This would be feasible if the diagnostic capability of post-contrast T 2 WI and DWI was comparable to that of pre-contrast T 2 WI and DWI in terms of detection and characterization of focal liver lesions. Gadoxetic acid increases magnetic susceptibility and shortens T 2 -relaxation time and may thus alter signal intensities on T 2 WI and DWI and apparent diŠusion coe‹cient (ADC) values.
We evaluated the eŠect of intravenous administration of gadoxetic acid disodium to hepatic lesions and liver parenchyma on T 2 WI and DWI.
Materials and Methods

Patients
This study followed the principles of the Declara-A. Muhi et al.
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tion of Helsinki. Our hospital's institutional review board approved the study; informed consent was waived. From January to April 2008, 101 consecutive patients (62 men, 39 women; aged 37 to 84 years; mean age, 65.4 years) who underwent magnetic resonance (MR) imaging for the evaluation of focal hepatic lesions were included in this study. All patients underwent DWI and T 2 WI before and after gadoxetic acid administration, and we retrospectively evaluated pre-and post-contrast images.
In the 101 consecutive patients, we assessed 259 focal hepatic lesions-145 hepatocellular carcinomas (HCCs) in 62 patients, 35 metastases in 10 patients, 2 cholangiocarcinomas (CCCs) in 2 patients, 15 hemangiomas in 11 patients, and 59 cysts in 26 patients.
Liver metastases originated from the following primary malignancies: colorectal carcinoma (26 lesions in 5 patients), breast carcinoma (3 lesions in 2 patients), pancreatic carcinoma (2 lesions in 1 patient), and gastric carcinoma (4 lesions in 2 patients). Lesion diameters ranged from 0.7 to 9.4 cm (mean, 1.7 cm). Speciˆcally, diameters ranged from 0.8 to 9.4 cm (mean, 1.8 cm) for HCCs; 0.8 to 8.4 cm (mean, 2.8 cm) for metastases; 0.9 to 3.8 cm (mean, 1.6 cm) for hemangiomas; and 0.7 to 4.5 cm (mean, 1.4 cm) for cysts; diameters of the 2 CCCs were 4.8 and 3.4 cm.
The diagnosis of HCC was conˆrmed by pathological examination (37 lesions in 21 patients) or on the basis of typical radiologicalˆndings described in the literature 10-13 using multi-imaging modalities. These included MR imaging, contrast-enhanced computed tomography (CT), CT during arteriography (CTA), and CT during arterial portography (CTAP) with intense enhancement in the arterial phase, contrast medium washout in the delayed phase, coronal enhancement, and progression of the disease presented on follow-up CT or MR images (108 lesions in 41 patients).
The diagnosis of metastases was conˆrmed by pathological examination (9 lesions in 5 patients) or on the basis of the histologicalˆndings of the primary tumor and observation of increased (21 lesions in 3 patients) or decreased (5 lesions in 2 patients) size after chemotherapy on follow-up dynamic contrast-enhanced CT and abdominal ultrasonography.
The diagnosis of hepatic hemangiomas was based on typicalˆndings that include nodular or globular enhancement with a gradualˆlling-in pattern on dynamic CT, very high signal intensity on both moderately and heavily T 2 -weighted images (T 2 WI), and lack of growth on CT or MR images during a follow-up period of at least 6 months.
Cysts were diagnosed on the basis of their typical appearance on nonenhanced T 1 WI (markedly low signal intensity) and T 2 WI (very high signal intensity on heavily T 2 WI and absence of contrast enhancement) and the lack of growth on CT or MR images during a follow-up period of at least 6 months.
MR imaging technique
All patients underwent MR imaging using a superconducting magnet operating at 1.5 tesla (Signa EXCITE HD; GE Medical Systems, Milwaukee, WI, USA) and an 8-channel phased-array coil. After pre-contrast T 1 W fast spoiled gradient-echo imaging, T 2 Wˆrst-spin echo images and diŠusion-weighted single-shot spin-echo echo-planar images were obtained. Dynamic images were obtained using fat-suppressed T 1 W gradient-echo imaging with a 3-dimensional (3D) acquisition sequence (liver acquisition with volume acceleration [LAVA]) before (pre-contrast) and 20 and 60 s and 2, 5, 10, and 20 min after intravenous administration of gadoxetic acid (0.025 mmol/kg body weight) followed by 20-mL saline ‰ush using a power injector (Sonic Shot 50; Nemoto, Tokyo, Japan). Pre-and postcontrast T 2 W fast spin-echo images were acquired using fat saturation (FS) and respiratory triggering. The post-contrast FS T 2 W images were obtained 13 min after the administration of gadoxetic acid. Parameters were: repetition time (TR)/echo time (TE), 3200 to 8000 ms/65 to 67 ms; ‰ip angle (FA), 909 ; number of signals acquired (NSA), one; matrix, 256×192; and acquisition time, 3 min.
DWI with motion-probing gradients in 3 directions was performed before and after administration of the contrast agent using the respiratory-triggered technique. Post-contrast DWI was performed after 20 min of hepatocyte-phase imaging under the following conditions: sequence, singleshot spin-echo echo-planar with parallel imaging technique (factor＝2); fat-suppression technique; spatially selective radiofrequency; scan direction, axial; b-value, 500 and 1000 s/mm 2 ; directions of diŠusion gradients, 3 orthogonal directions; TR/ TE/time of inversion (TI)＝8000 to 10000 ms/73.2 to 73.4 ms/70 ms; matrix, 128×128; slice number, 60; slice thickness, 4 to 6 mm;ˆeld of view (FOV), 40 cm; number of signal averages (NSA), 4; and acquisition time, approximately 5 to 6 min.
Image analysis
We performed quantitative image analysis by measuring the signal intensity of the liver parenchyma, focal hepatic lesions, and skeletal muscles using operator-deˆned regions of interest (ROIs) for each image. We measured the signal intensity ratio (SIR) of the liver parenchyma and focal hepatic lesion and the lesion-liver contrast intensity ratio (CIR) for both pre-and post-contrast DWI and T 2 WI using the following 3 formulae: SIR of liver parenchyma＝signal intensity of liver/signal intensity of skeletal muscle [1] . SIR of hepatic lesion＝ signal intensity of the hepatic lesion/signal intensity of skeletal muscle [2] . CIR＝(signal intensity of lesion-signal intensity of liver)/signal intensity of skeletal muscle [3] .
ADC measurements of the hepatic parenchyma and focal hepatic lesions were obtained and used for quantitative analysis. Three ROIs were drawn over each lesion and the hepatic parenchyma on DW images of diŠerent b-values (500 and 1000 s/ mm 2 ). We carefully placed the ROIs within the connes of each lesion. As a rule, we placed the ROIs for heterogeneous lesions to include the entire lesion and not to exclude various components with diŠerent attenuation values. We placed the ROIs of the liver parenchyma in the right lobe. In this manner, we measured signal intensity 3 times and obtained an average of the 3 measurements for each lesion and the hepatic parenchyma.
We calculated ADC values using the formula:
where Ln is the natural logarithm, and SI1 and SI2 are the signal intensity measurements obtained for moderate bvalue (b1, 500 s/mm 2 ; SI1) and high b-value (b2, 1000 s/mm 2 ; SI2) DWI. All ADC values were expressed as mean±standard deviation. One radiologist with 5 years' experience in abdominal radiography performed all SIR, CIR, and ADC measurements.
Two abdominal radiologists blinded to the clinical history of patients andˆnal diagnosis retrospectively performed qualitative assessment by consensus reading using a commercially available picture archiving and communication system (SYNAPSE, Fujiˆlm Medical, Tokyo, Japan). To decrease memory bias, T 2 WI and DWI were interpreted on diŠerent days at an interval of 2 weeks. Lesion detectability was calculated and compared between pre-and post-contrast T 2 WI and DWI, and the 2 radiologists visually assessed and classiˆed lesions into 5 categories: 1, detected on pre-contrast images only; 2, detected on pre-and post-contrast images but clearer on pre-contrast images; 3, detected on pre-and post-contrast images with comparable clarity; 4, detected with pre-and post-contrast images but clearer on post-contrast images; and 5, detected on post-contrast images only.
Statistical analysis
We classiˆed all hepatic lesions into 2 groups as either malignant (including HCCs, metastases, and CCCs) or benign (including hemangiomas and cysts); used paired sample t test to compare SIR, CIR, and ADC between the pre-and post-contrast images; used Pearson correlation to assess the bivariate correlation between the pre-and post-contrast T 2 WI and DWI; and used Mann-Whitney test to compare the ADC values of the 2 groups (malignant and benign lesions). We used chi-square test to assess the statistical diŠerence in lesion detectability between the pre-and post-contrast T 2 W and DW images. For all the tests, Pº0.05 was considered signiˆcant diŠerence. Statistical analyses were performed using version 16 of Statistical Package for Social Science (SPSS for Windows; SPSS Japan, Tokyo, Japan).
Results
T 2 WI
The SIRs of the liver parenchyma, malignant tumors, and benign lesions were comparable between pre-and post-contrast T 2 One more malignant lesion was detected by pre-(46.7z, 85/182) than post-contrast T 2 WI (46.1z, 84/182), but detectability of malignant and benign lesions did not diŠer signiˆcantly between pre-and post-contrast T 2 WI (Figs. 1, 2) .
Bivariate correlation analysis revealed a strong correlation between SIR and CIR of pre-and postcontrast T 2 WI (correlation coe‹cient range, 0.735 to 0.917) ( Table 1) .
DWI
The mean SIR of the liver parenchyma was signiˆcantly decreased on post-contrast DWI (1.4± 0.68, 1.71±0.67) compared to pre-contrast DWI (1.89±0.68, 2.26±0.78) at b-values of 500 and 1000 s/mm 2 ( Pº0.001). The mean ADC value of the liver parenchyma was signiˆcantly higher on pre-contrast (0.77±0.32 mm 2 /s) than post-contrast Table 2) . We did not calculate the SIRs, CIRs, and ADC for hepatic cysts because only 6 cysts were detected on DWI at b-value＝1000 s/mm 2 .
The SIRs, CIRs, and ADCs of malignant lesions and hemangiomas were comparable on pre-and post-contrast DWI (Table 2) . ADC values were lower for malignant lesions (pre-, 0.94±0.41 mm 2 /s; post-, 0.92±0.41 mm 2 /s) than hemangiomas (pre-, 1.41±0.29 mm 2 /s; post-, 1.33±0.34 mm 2 /s) on both pre-and post-contrast DWI ( Pº0.0001) ( Table 2) .
Lesion detectability did not diŠer signiˆcantly between pre-and post-contrast DWI (Figs. 2, 3) . However, 14 focal hepatic lesions showed discrepancies between pre-and post-contrast images. Lesions visible only on post-contrast images included 4 HCC, 3 metastases, and one hemangioma, and those visible only on precontrast images included 4 HCC, one case of metastasis, and one cyst.
Bivariate correlation analysis revealed fair-tostrong correlation between the SIR, CIR, and ADC of the pre-and post-contrast DW images (correlation coe‹cient range, 0.227 to 0.793). Data represent means±standard deviation (SD). 
Discussion
In our study, the SIRs and CIRs of the liver and focal hepatic lesions were comparable on pre-and post-contrast T 2 WI. However, the SIR and ADC of the liver on DWI were decreased after gadoxetic acid administration, perhaps because of the relative T 2 *-shortening eŠect of gadoxetic acid.
Though the ADC of the liver was signiˆcantly lower on post-contrast images, ADC values of the focal hepatic lesions were comparable on pre-and post-contrast images. Our result indicates that administration of gadoxetic acid does not aŠect the signal intensity with DWI or ADC values of the focal liver lesions that usually show no or minimal uptake of the contrast agent.
To evaluate the eŠect of gadoxetic acid on lesion characterization, we compared the ADC values of malignant and benign lesions on pre-and post-contrast DWI. Our results indicate comparable lesion characterization between DWI obtained after gadoxetic acid administration and pre-contrast images, possibly as a result of elimination of most of the contrast agent, even in hypervascular lesions, after the 20-min delay for hepatocyte phase image.
With regard to lesion detectability, 4 HCCs were detected using pre-contrast DWI only, and the 4 other HCCs were detected using post-contrast DWI only. None of the 4 HCCs that is not detected on post-contrast DWI showed signiˆcant signal increase after gadoxetic acid administration. That suggests that the signal change in the liver parenchyma did not aŠect the conspicuity of HCC lesions. Two additional metastases were detected using post-contrast DWI only, but the reason for this discrepancy is unclear. Because hepatocyte-phase imaging can be acquired 10 to 20 min after injection of the gadoxetic acid, 9 T 2 WI and DWI can be obtained between the dynamic (5 min) and hepatocyte (20 min) phases to shorten examination time.
Choi's group reported similar results using a 3T MR system. 14 They reported that DWI after gadoxetic acid administration can be substituted for precontrast DWI without compromising contrast-tonoise ratio and ADC of the focal hepatic lesions. In another study, Kim and associates reported comparable diagnostic capability for T 2 WI after gadoxetic acid administration and pre-contrast T 2 WI for the detection and characterization of hepatic tumors. 15 On the other hand, the teams of Tamada 16 and Saito 17 reported that late acquisition of T 2 WI and DWI after gadoxetic acid administration can aŠect signal drop of the liver parenchyma. Considering those previous results, however, most researchers concluded that DWI and T 2 WI after gadoxetic acid administration can be substituted for those before contrast. 2, [15] [16] [17] We applied 2 non-zero or high b-values (b＝500 and 1000 s/mm 2 ) to obtain ADC values. The choice of 2 high b-values over conventional b-values, e.g., b＝0 and 1000 s/mm 2 , has some advantage. First, the ADC value calculated using 2 high b-values can be considered unaŠected by microcirculation or regarded as re‰ecting pure diŠusion. Second, DWI with b＝500 is clinically useful toˆnd a lesion together with b＝1000 s/mm 2 images, whereas b＝0 s/mm 2 image usually has no clinical use. On the other hand, we should be aware that our results for ADC values cannot be compared with those in the other study using b＝0 s/mm 2 as the lower b-value because of the in‰uence of microcirculation on results.
Our study was limited by our small number of patients, the absence of histopathological conˆr-mation for some lesions, and our inability to calculate interreader agreement because we evaluated focal hepatic lesions and measured ADC by consensus reading.
In conclusion, our results suggest that acquisition of T 2 W and DW images during the hepatocyte phase can be feasible and does not compromise the SIR, CIR, and ADC values of focal hepatic lesions. However, the signal intensity of DWI and ADC value of the liver parenchyma were decreased on gadoxetic acid-enhanced hepatocyte phase images.
